Podcast
17 Nov 2026
3 mins

Wave Neuro CEO Fred Walke on This is Cruxx Podcast

Blair Atkins
Director of Brand and Growth

Why are we giving every brain the same TMS treatment?

That’s the question Wave Neuroscience CEO Fred Walke explores with host Liz Moyles on the latest episode of This is Cruxx. Over the course of the conversation, they discuss how personalized, data-driven care could change the way we approach mental health.

A personal path to precision neuromodulation

Fred became a CEO at 29 and built his early career in the dental industry. A deeply personal experience later inspired him to found Wave Neuroscience, a company built on the belief that every patient deserves care designed around their own brain.

Guided by each patient’s brain 

Traditional TMS often relies on standardized protocols. MeRT® takes a different approach and uses each patient’s EEG data to personalize treatment. Fred explains why objective brain measurements matter alongside symptom-based assessments and how they can give clinicians a clearer picture of each patient.

From research to FDA clearance

Fred and Liz also talk about MeRT’s path to FDA clearance and what it took to bring a new, personalized option to people living with PTSD.

Removing barriers to care

Even with new options available, many patients still face real obstacles to treatment, including cost, insurance coverage, location and time. Fred shares how the Just One Wave Foundation is working to expand access for underserved communities.

It’s a thoughtful conversation about where mental healthcare is headed. We’re grateful to Liz and This is Cruxx for having Fred on the show.

‍

Listen on Apple Podcasts

Listen on Spotify

MeRT is FDA-cleared for treatment of adults with PTSD. Individual results may vary.

‍

‍

Share this post
Copied